Rabies virus glycoprotein (RVG) - antigenic site I (RVG site I)

The Rabies virus glycoprotein (RVG) is the sole protein exposed on the surface of the rabies virus envelope and is the primary target for neutralizing antibodies. Antigenic site I is a specific, highly conserved conformational epitope located on the RVG that plays a critical role in the virus's ability to infect host cells. This site is involved in the structural transitions of the glycoprotein during membrane fusion and is a major target for both natural immune responses and therapeutic monoclonal antibodies. In the context of post-exposure prophylaxis (PEP), drugs targeting this site aim to neutralize the virus before it can enter the central nervous system. Because the rabies virus is nearly 100% fatal once symptoms appear, the integrity and accessibility of antigenic site I are vital for the efficacy of vaccines and passive immunization strategies. Research into this epitope is also essential for monitoring viral evolution and the emergence of escape mutants that could bypass existing treatments.

Other names

Antigenic site IEpitope I of Rabies virus glycoproteinRabies virus G protein antigenic site IRVG site I

Neutralization of the rabies virus by binding to the glycoprotein, thereby preventing viral attachment to host cell receptors (such as nicotinic acetylcholine receptors) and inhibiting the pH-dependent membrane fusion process required for viral entry into the cytoplasm.